BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2021;11:737767. [PMID: 34760699 DOI: 10.3389/fonc.2021.737767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Yin H, Fu X, Gao H, Gao H, Ma Y, Chen X, Zhang X, Du S, Qi Y. Hybrid peptide NTP-217 triggers ROS-mediated rapid necrosis in liver cancer cells by induction of mitochondrial leakage. Front Oncol 2023;12. [DOI: 10.3389/fonc.2022.1028600] [Reference Citation Analysis]
2 Sacco R, Ramai D, Tortora R, di Costanzo GG, Burlone ME, Pirisi M, Federico P, Daniele B, Silletta M, Gallo P, Cocuzza C, Russello M, Cabibbo G, Rancatore G, Cesario S, Masi G, Marzi L, Mega A, Granito A, Pieri G, Giannini EG, Paolillo R, Gadaleta-Caldarola G, Dadduzio V, Giordano G, Giacomelli L, Papa S, Renzulli M, Maida M, Ghidini M, Borzio M, Facciorusso A; A.I.G.O. (Italian Association of Hospital Gastroenterologists). Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis. Cancers (Basel) 2023;15. [PMID: 36672330 DOI: 10.3390/cancers15020381] [Reference Citation Analysis]
3 Luo J, Gao B, Lin Z, Fan H, Ma W, Yu D, Yang Q, Tian J, Yang X, Li B. Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis. Front Oncol 2022;12:1010726. [PMID: 36620586 DOI: 10.3389/fonc.2022.1010726] [Reference Citation Analysis]
4 Hsu PY, Liang PC, Chang WT, Lu MY, Wang WH, Chuang SC, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Chuang WL, Huang CF, Huang JF, Yu ML. Artificial intelligence based on serum biomarkers predicts the efficacy of lenvatinib for unresectable hepatocellular carcinoma. Am J Cancer Res 2022;12:5576-88. [PMID: 36628276] [Reference Citation Analysis]
5 Stępniak J, Krawczyk-Lipiec J, Lewiński A, Karbownik-Lewińska M. Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: Effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines 2022;10. [PMID: 36428458 DOI: 10.3390/biomedicines10112890] [Reference Citation Analysis]
6 Wang S, Wang Y, Yu J, Wu H, Zhou Y. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14. [PMID: 36428618 DOI: 10.3390/cancers14225525] [Reference Citation Analysis]
7 Petkau VV, Sultanbaev AV, Menshikov KV, Antipin AS, Volkonsky MV, Filippova VM, Vasilyeva YV, Tarkhanov AA, Mukhitova MR, Murzalina MZ, Safarova AR. Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice. Rossijskij žurnal gastroènterologii, gepatologii, koloproktologii 2022;32:75-88. [DOI: 10.22416/1382-4376-2022-32-4-75-88] [Reference Citation Analysis]
8 Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC). Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open. [DOI: 10.1002/jgh3.12772] [Reference Citation Analysis]